 |
Events
We invite you to visit PAREXEL at these upcoming industry events. Events are a great way to get to know our experts, discuss your outsourcing challenges, and learn how PAREXEL’s global reach, technology and expertise can help your organization.
Read More
|
|
| Featured Viewpoint on Understanding the Challenges of Biosimilar Medicines |
|
As major biological medicines currently on the market approach the end of their patent protection, drug manufacturers around the world are exploring the possibility of producing “generic” biopharmaceuticals – known as “biosimilars” or “follow-on proteins” – that would increase the availability and lower the price of these life-saving products.
Read more... |
| Expert Profile: |
|
Cecil Nick, Vice President, Biotechnology, PAREXEL Consulting
For more than 20 years, Cecil Nick has helped biopharmaceutical companies bring important new products to market to benefit patients around the world. Through his consulting work and tireless participation in global industry events, Mr. Nick has advocated a better understanding of the inter-relationship between chemical, biological, and clinical data – knowledge that speeds the development of safer and more effective medicines. He joined PAREXEL in 2001.
Read more... |
| Best Practices: Lessons learned from biosimilar development in the EU |
|
The European Union (EU) has pioneered the field of biosimilar products. The key EU Directive (2001/83) which provides the framework for regulation of medicines describes a biosimilar as a biological medicinal product which is similar to a reference biological product, but does not meet the conditions in the definition of a generic medicinal product because of differences in manufacturing processes.
Read more... |
|
